Knight Therapeutics Inc., of Montreal, has purchased global rights to Impavido (miltefosine) as a result of the termination of its agreement with Paladin Labs (Barbados) Inc., an affiliate of Endo International plc, of Dublin, related to the distribution and sale of Impavido in all countries other than the U.S. The company said that it is committed to ensuring the continued supply of the medicine, which is a treatment for leishmaniasis, a parasitic disease that is found in parts of the tropics, subtropics, and southern Europe.